FLINT, Mich. – March 6, 2017 – The nation’s largest independent specialty pharmacy has been selected to the limited-distribution panel of XERMELO™ (telotristat ethyl).

Diplomat Pharmacy, Inc. (NYSE: DPLO), will fill prescriptions for XERMELO™ (telotristat ethyl), the first oral therapy for adults whose carcinoid syndrome diarrhea is inadequately controlled by somatostatin analog (SSA) therapy.

XERMELO™ was recently approved with orphan status by the Food and Drug Administration.

To learn more about Diplomat’s rare disease program, visit diplomat.is/areas-of-excellence/rare-diseases.

“XERMELO™ is a promising new treatment option,” said Paul Urick, Diplomat’s president. “Carcinoid syndrome is life-altering to those who suffer from it, and now we are able to help them. XERMELO™ will help us deliver the personal support we promise patients and make a real impact on their treatment.”

Carcinoid syndrome occurs when metastatic carcinoid tumors overproduce certain chemicals such as serotonin. XERMELO™ targets tryptophan hydroxylase, an enzyme responsible for excess serotonin production. XERMELO™ works within tumorous cells to reduce serotonin production, providing more control for patients over the disease.

Symptoms of carcinoid syndrome (such as facial flushing, abdominal pain, heart valve damage, and frequent diarrhea) often prevent patients from leading active, plannable lives. According to the American Society of Clinical Oncology, about 12,000 people in the U.S. are diagnosed with a carcinoid tumor each year.

XERMELO™ is manufactured by Lexicon Pharmaceuticals, Inc. For full prescribing information, click here. 

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give current expectations or forecasts of future events or our future financial or operating performance. The forward-looking statements contained in this press release are based on management’s good-faith belief and reasonable judgment based on current information. These statements are qualified by important risks and uncertainties, many of which are beyond our control, that could cause our actual results to differ materially from those forecasted or indicated by such forward-looking statements. For a discussion of such risks and uncertainties, you should review Diplomat’s filings with the Securities and Exchange Commission, including “Risk Factors” in Diplomat’s Annual Report on Form 10-K for the year ended Dec. 31, 2015, and in subsequent reports filed with or furnished to the Securities and Exchange Commission. Except as may be required by any applicable laws, Diplomat assumes no obligation to publicly update such forward-looking statements, which are made as of the date hereof or the earlier date specified herein, whether as a result of new information, future developments or otherwise.

About Diplomat

Diplomat (NYSE: DPLO) serves patients and physicians in all 50 states. Headquartered in Flint, Michigan, the company focuses on medication management programs for people with complex chronic diseases. Diplomat opened its doors in 1975 as a neighborhood pharmacy with one essential tenet: “Take good care of patients and the rest falls into place.” Today, that tradition continues—always focused on improving patient care and clinical adherence. For more information, visit diplomat.is.


Kali Lucas, Public Relations Specialist
810.768.9580 | press@diplomat.is

Gary Rice, RPh, MS, MBA, CSP
Executive Vice President of Operations
810.768.9863 | grice@diplomat.is